NasdaqCM - Nasdaq Real Time Price USD

Alterity Therapeutics Limited (ATHE)

Compare

2.9400

-0.3900

(-11.71%)

At close: January 24 at 4:00:00 PM EST

3.0700

+0.08

+(2.68%)

Pre-Market: 4:31:26 AM EST

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November 2024Positive interim data presented at MDS from the ATH434-202 Phase 2 trial in advanced MSAMultiple data presentations and publications showing the potential for ATH434 to modify disease progression in neurodegenerative conditionsCash balance on 31 December 2024 of A$4.54 m MELBOURNE, Australia and SA

GlobeNewswire 2 days ago

ATHE
-11.71%
PRNAF
Alterity CEO says ‘filled with optimism for 2025’

Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity Therapeutics… 2024 was a year of significant progress for Alterity. Most prominently, we completed our 12-month, double-blind Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy. This milestone leads us to a topline data readout expected in late January or early February. Last J

TipRanks 16 days ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Valued Shareholders: As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity Therapeutics. I want to express my sincere gratitude for your unwavering sup

GlobeNewswire 17 days ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-201 Phase 2 trial, a randomized, doub

GlobeNewswire last month

ATHE
-11.71%
PRNAF
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the

GlobeNewswire 2 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International Symposium on the Autonomic Nervous System. “The data presented highligh

GlobeNewswire 2 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodeg

GlobeNewswire 2 months ago

ATHE
-11.71%
PRNAF
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System AtrophyMultiple data presentations at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS)Appointed Abby Macnish Niven as Chief Financial OfficerCash balance on 30 September 2024 of A$9.28m MELBOURN

GlobeNewswire 2 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 Oc

GlobeNewswire 3 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuc

GlobeNewswire 3 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presenta

GlobeNewswire 3 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company’s Chief Financial Officer (CFO), effective today. “We look forward to Abby’s contributions whose broad experience and financial background will help us advance our programs. I

GlobeNewswire 3 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations will be presented at the

GlobeNewswire 4 months ago

ATHE
-11.71%
PRNAF
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in some patientsData from the bioMUSE Natural History Study continues to characterize early stage MSA and inform Alterity’s Phase 2 clinical trialsMultiple data presentations at the World Orphan Drug Congress and the American Academy of Neurology (AAN) Annual MeetingCash balance on 30 June 2024 of A$12.6M

GlobeNewswire 5 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics to Present at MST Financial Webinar

MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data fo

GlobeNewswire 6 months ago

ATHE
-11.71%
PRNAF
Alterity (ATHE) Up on Interim Data From Advance MSA Study

Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.

Zacks 6 months ago

ATHE
-11.71%
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to develo

GlobeNewswire 6 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United State

GlobeNewswire 7 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesda

GlobeNewswire 7 months ago

ATHE
-11.71%
PRNAF
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH43

GlobeNewswire 8 months ago

ATHE
-11.71%
PRNAF

Performance Overview

Return	ATHE	S&P/ASX 200 [XJO]
YTD	-16.00%	+3.06%
1-Year	+53.13%	+11.83%
3-Year	-61.32%	+17.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alterity Therapeutics Limited (ATHE)

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Alterity CEO says ‘filled with optimism for 2025’

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Alterity Therapeutics to Present at MST Financial Webinar

Alterity (ATHE) Up on Interim Data From Advance MSA Study

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Performance Overview